GLP-1s: A Quiet Drop-Off in Seniors
For many seniors, breakthrough weight-loss drugs deliver real benefits — until insurance denials, side effects, or muscle loss force them to quit.
By
Paula Span
January 6, 2026
Clinical Scorecard: GLP-1s: A Quiet Drop-Off in Seniors
At a Glance
Category Detail
Condition Obesity and Type 2 Diabetes in Older Adults Key Mechanisms GLP-1 receptor agonists promote weight loss and improve glycemic control. Target Population Adults aged 65 and older, particularly those with obesity and Type 2 diabetes. Care Setting Primary care and specialty clinics.
Key Highlights
Approximately 40% of older adults have obesity, with nearly 30% having Type 2 diabetes. 60% of seniors with diabetes discontinue semaglutide within a year. Common side effects include gastrointestinal issues such as nausea and diarrhea. Muscle loss can occur with GLP-1 use, leading to frailty and increased fall risk. Cost and insurance coverage are significant barriers to continued use of GLP-1 medications. Guideline-Based Recommendations
Diagnosis
Assess body mass index (BMI) and consider diabetes status in older adults. Management
Consider GLP-1 receptor agonists for weight management in eligible patients. Monitoring & Follow-up
Regularly monitor weight, blood glucose levels, and side effects. Risks
Monitor for gastrointestinal side effects and potential muscle loss. Patient & Prescribing Data
Older adults, particularly those with obesity and Type 2 diabetes.
Medications may require long-term use for sustained benefits; cost is a major factor in adherence.
Clinical Best Practices
Encourage exercise and strength training to mitigate muscle loss. Educate patients on the necessity of long-term medication adherence. Advocate for insurance coverage changes to improve access to GLP-1 medications. Related Resources & Content
